OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
180,000
+20,600 (12.92%)
Feb 27, 2026, 3:30 PM KST
223.74%
Market Cap 3.63T
Revenue (ttm) 10.18B
Net Income (ttm) -43.30B
Shares Out 20.19M
EPS (ttm) -2,280.15
PE Ratio n/a
Forward PE 330.38
Dividend n/a
Ex-Dividend Date n/a
Volume 816,375
Average Volume 400,913
Open 160,900
Previous Close 159,400
Day's Range 160,400 - 185,500
52-Week Range 34,500 - 185,500
Beta 0.55
RSI 71.05
Earnings Date Mar 20, 2026

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2024, OliX Pharmaceuticals's revenue was 5.68 billion, a decrease of -66.73% compared to the previous year's 17.06 billion. Losses were -40.66 billion, 112.9% more than in 2023.

Financial Statements

News

There is no news available yet.